Grass City 20% OFF

PALM BEACH, Florida, October 19, 2017 /PRNewswire/ —

In a report issued this year by Ameri Research Inc. [ ] , they estimate Global Cannabis Industry was valued at $14.3 Billion in 2016 and is forecast to grow at a CAGR of 21.1% between 2017 and 2024, culminating in 2024 Global Sales of $63.5 Billion. The Global Market is witnessing robust growth owing to the increasing legalization and decriminalization of marijuana across North America, Europe and many other Countries. The rising demand of marijuana for recreational use and medical use is a key factor driving the growth for companies such as:MYM Nutraceuticals Inc. (CNSX:MYM.CN), India Globalization Capital, Inc. , Supreme Pharmaceuticals Inc. , Aphria Inc. , Medical Marijuana, Inc. .

MYM Nutraceuticals Inc. (OTCQB:MYMMF) (CNSX:MYM-CN.CN) announced that it has entered into a strategic partnership with PUF Ventures Inc. (CNSX:PUF.CN) (“PUF”) for the construction of a one million square foot greenhouse facility in northern New South Wales Australia called the Northern Rivers Project. The Northern Rivers Project is a partnership with the Richmond Valley Council-the local government in New South Wales, Australia-and PUF Ventures Australia (“PVA”)-a recently formed majority-owned subsidiary of PUF-to construct a one million square foot greenhouse operation, with large-scale manufacturing, processing and office facilities for the cultivation, production and manufacture of medical cannabis and associated products. Read this and more news for MYM Nutraceuticals at:

MYM will own 35% of the Northern Rivers Project, which, at full scale, will have the capacity to produce 100,000 kilograms of high quality cannabis per year, worth between C$800 million and C$1.1 billion (based on current pricing metrics in the Australian cannabis marketplace). Australia has introduced progressive medical cannabis laws in the past few years, and are essentially where Canada was four years ago. Assuming recreational cannabis becomes legal and with a population of more than 24 million people, it is estimated that the cannabis market in Australia will grow to C$9 billion over the next 7 years making it a very attractive market. Being one of the first large-scale production facilities in the Australian market, MYM and PUF could capture a significant portion of that potential revenue. By entering this market through a strategic partnership with the local land-owning government, MYM is positioning itself to become a leader in both Australian and global cannabis production.

The Northern Rivers Project includes a land purchase option agreement with the Richmond Valley Council for a 27-hectare parcel of land near the town of Casino in northern New South Wales, Australia. This is a landmark agreement whereby the council will provide the land for five years at no cost, with an option for Northern Rivers Project to purchase the parcel on favorable terms after the fifth year. The Richmond Valley Council has been extremely supportive of Northern Rivers Project’s growth strategy and vision and is committed to improving local economic and employment opportunities. The purchase agreement and associated partnership with the Richmond Valley Council will allow the Northern Rivers Project to enter the cannabis market on a solid footing with the full support of the local political and governing bodies. Having the largest medical cannabis facility in the southern hemisphere in Richmond Valley is expected to draw other investments in research, education, manufacturing, tourism, and other sectors.

Vaughan Macdonald, General Manager of Richmond Valley Council, stated that they are very excited to be working together on the Northern Rivers Project with international partners and fully support the development of this important new industry which will significantly add to gross regional product, create approximately 300 direct new jobs in the local economy, and lead to other follow-on local and regional employment opportunities.

In other industry news of note:

India Globalization Capital, Inc. yesterday provided compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model, showing that at varying concentrations of IGC-AD1 the expression of GSK3beta is reduced by as much as 62%, leading in turn to a reduction in hyper phosphorylation of tau protein. “Based on this and other previously announced compelling data, we are readying IGC-AD1, brand name Hyalolex, in a liquid formulation for commercialization in early 2018,” stated IGC’s CEO, Ram Mukunda. We have identified Germany, Canada and certain licensed medical cannabis states in the U.S. for commercialization. The German market recently opened for imports of cannabis products that can be sold in licensed pharmacies. Our initial research indicates that there are about 7.8 million patients with AD in these combined markets.

Supreme Pharmaceuticals Inc. announced this week that it has amended its agreement with Canaccord Genuity Corp., as lead underwriter on behalf of a syndicate of underwriters (the “Underwriters”), to increase the size of its previously announced bought deal private placement of convertible debenture units (the “Convertible Debenture Units”) to $35,000,000 . Under the terms of the amending agreement, the underwriters will now have an option to acquire up to 5,250 additional Convertible Debenture Units, each having the same terms as the Convertible Debenture Units above, which option is exercisable until the Closing Date (as hereinafter defined).All other previously announced terms of the Offering (as hereinafter defined) remain unchanged. As previously announced, each convertible debenture unit will consist of $1,000 principal amount of 8 per cent senior unsecured convertible debentures and 313 common share purchase warrants of the company.

Aphria Inc. (OTCQB:APHQF) last week reported its results, for the first quarter ended August 31, 2017. “In the first quarter of 2018, Aphria increased revenue and grams sold and lowered cash costs, in addition to recording our eighth consecutive quarter of positive EBITDA,” said Vic Neufeld, Chief Executive Officer, Aphria. “A key driver of our continued performance has been our ability to maintain leadership as one of the lowest-cost producers in the industry. As legal recreational cannabis comes into market in 2018, low costs per gram will be a critical factor for the entire supply chain. Our proven ability to grow to scale while keeping costs low is an important competitive advantage; it positions Aphria to profitably meet projected demand for cannabis and deliver sustainable value to our shareholders.”Read the full release at

Medical Marijuana, Inc. , the first-ever publicly traded cannabis company in the United States, announced yesterday that its subsidiary Kannaway(R) LLC is welcoming Robert “Bo” Brannin as its new Senior Director of Operations.In this position, Brannin will be responsible for managing every aspect of the company’s supply chain operations from purchasing to inventory, production and shipping. He will bring his twenty years of experience in the operations and logistics field to assist the team in building a strong foundation as the company now prepares to establish international operations. (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein.MNU and its affiliated companies is a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.MNU’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.For current services performed MNU has been compensated forty four hundred dollars for news coverage of the current press release issued by MYM Nutraceuticals Inc.. by a non-affiliated third party.MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information:        +1(561)325-8757